Literature DB >> 18173926

Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate.

G-Y Gwak1, K C Koh, H-Y Kim.   

Abstract

A 66-year-old female patient with rheumatoid arthritis, who had been HBsAg-negative and anti-HBs-positive, developed hepatic dysfunction following low-dose methotrexate therapy. Serologic testing for HBsAg, HBeAg, IgM HBc and HBV DNA were positive. Despite antiviral therapy with lamivudine, the hepatic condition gradually deteriorated until the patient died. Since HBV replication persists in the liver even in individuals with resolved HBV infection (i.e., HBsAg-negative, anti-HBs-positive), HBV reactivation may occur in these patients with immunosuppression. Therefore, especially in endemic areas, all patients being considered for immunosuppressive therapy should be closely monitored with liver function tests and evaluated for HBV reappearance even when HBsAg-negative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173926

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  20 in total

1.  Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2017-01-05       Impact factor: 6.047

2.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

3.  Adverse effects of methotrexate in three psoriatic arthritis patients.

Authors:  Hideki Maejima; Akira Watarai; Toshiaki Nakano; Chieko Katayama; Hiromi Nishiyama; Kensei Katsuoka
Journal:  Rheumatol Int       Date:  2012-12-29       Impact factor: 2.631

Review 4.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

5.  Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.

Authors:  Jing Tan; Jingguo Zhou; Pan Zhao; Jing Wei
Journal:  Clin Rheumatol       Date:  2012-04-28       Impact factor: 2.980

6.  Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.

Authors:  Akihiro Tamori; Tatsuya Koike; Hitoshi Goto; Shigeyuki Wakitani; Masahiro Tada; Hiroyasu Morikawa; Masaru Enomoto; Masaaki Inaba; Tatsuya Nakatani; Masayuki Hino; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2011-01-19       Impact factor: 7.527

Review 7.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

Review 8.  Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure.

Authors:  En-Qiang Chen; Fan Zeng; Ling-Yun Zhou; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

Review 10.  Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.

Authors:  Fernando Bessone; Melisa Dirchwolf
Journal:  World J Hepatol       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.